Abstract: The present invention provides a device for securing to the stem of an eyeglass frame comprising (a) a sleeve member having an inner surface and an outer surface; (b) a dividing member within said sleeve member, said dividing member having a first edge and a second edge, said first edge being secured to the inner surface of said sleeve member along a first line and said second edge being secured to a second line that is substantially parallel to said first line and spaced there from to thereby define a first channel and a second channel within said sleeve member, said first channel being configured for receiving an eyeglass stem and securing said device to said eyeglass stem and said second channel being configured for retaining an anchor member within said sleeve member; and (c) a clip comprising an anchor member and an arm, said anchor member being retained within said second channel and said anchor member having a first edge and said being arm secured to said first edge of said anchor member and oriented o
Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Type:
Grant
Filed:
July 6, 2004
Date of Patent:
August 29, 2006
Assignee:
Allergan, Inc.
Inventors:
Steven W. Andrews, Julie A. Wurster, Clarence E. Hull, III
Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
Abstract: The present invention relates to novel pharmaceutical compositions of bimatoprost and other cyclopentane(ene) heptan(en)oic acid amides and their use in preventing sunburn and/or providing an artificial tan to human skin.
Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Type:
Grant
Filed:
April 1, 2003
Date of Patent:
June 13, 2006
Assignee:
Allergan, Inc.
Inventors:
Steven W. Andrews, Xialing Guo, Zhen Zhu, Clarence E. Hull, III, Julie A. Wurster, Shimiao Wang, Edward H. Wang, Thomas Malone
Abstract: The present invention provides prostamide receptor antagonist compounds that may be represented by the general formula I. wherein A, R1, R2, R3, R4 and R6 are as defined in the specification.
Abstract: The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I: wherein the hatched segment represents an ? bonds, the solid triangle represents a ? bond, the wavy segments represent ? or ? bond, dashed lines represent a double bond or a single bond, X is selected from the group consisting of hydrogen and halogen radicals, R3 is heteroaryl or a substituted heteroaryl radical, R1 and R2 are independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon atoms, R is selected from the group consisting of CO2R4, CONR42, CH2OR4, CONR4SO2R4, P(O)(OR4) and wherein R4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4.
Type:
Grant
Filed:
November 4, 2003
Date of Patent:
April 4, 2006
Assignee:
Allergan, Inc.
Inventors:
Robert M. Burk, Mark Holoboski, Mari F. Posner
Abstract: A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I, wherein Y is (CH2)x; Z is selected from the group consisting of and (CR2)x, x is an integer of 1 or 2; n is 0 or 1; R2 is hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteroatom is
Type:
Grant
Filed:
September 17, 2004
Date of Patent:
March 28, 2006
Assignee:
Allergan, Inc.
Inventors:
Robert M. Burk, Achim H-P Krauss, David F. Woodward
Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Type:
Grant
Filed:
February 20, 2004
Date of Patent:
March 21, 2006
Assignee:
Allergan, Inc.
Inventors:
Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound which is a EP4 agonist.
Type:
Grant
Filed:
September 26, 2003
Date of Patent:
October 18, 2005
Assignee:
Allergan, Inc.
Inventors:
David F. Woodward, Achim H. Krauss, Robert M. Burk, Mark Holoboski, Mari F. Posner
Abstract: Compounds of Formula 1 Formula 1 where the symbols have the meaning described in the specification, and particularly the compound of Formula 3 Formula 3 (tazarotene) exhibit synergistic anti-proliferative effect with human recombinant interferon in the treatment of solid tumors and leukemia, particularly breast cancer and acute myeloid leukemia.
Type:
Grant
Filed:
August 17, 2000
Date of Patent:
June 7, 2005
Assignee:
Allergan, Inc.
Inventors:
Alissar Nehme, Richard L. Beard, Roshantha A. Chandraratna
Abstract: The present invention relates to an agent comprising a neurotoxin, methods for making the agents and methods for treating endocrine disorders, for example gonadotrophin related illnesses. Preferably, the agent comprises at least a portion of a botulinum toxin.
Abstract: Methods for treating endocrine disorders and for inhibiting gametogenesis by intracranial administration to a human patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A.
Abstract: According to the invention there is provided a compound the formula I;
wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
Abstract: Methods for treating the hypothyroidism of Hashimoto's thyroiditis by local administration of a Clostridial toxin, such as a botulinum toxin, to the thyroid gland of a patient.
Abstract: A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I,
wherein Y is (CH2)x; Z is selected from the group consisting of
x is an integer of 1 or 2; n is 0 or 1; R2 is hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein t
Type:
Grant
Filed:
August 5, 2002
Date of Patent:
November 16, 2004
Assignee:
Allergan, Inc.
Inventors:
Robert M. Burk, Achim H-P Krauss, David F. Woodward
Abstract: The present invention provides a compound represented by the general formula I;
wherein A, Ar, X, Z, n, x, y, R and R3 are as defined in the specification.
Type:
Grant
Filed:
January 26, 2004
Date of Patent:
November 2, 2004
Assignee:
Allergan, Inc.
Inventors:
David W. Old, Thang D. Dinh, Robert M. Burk
Abstract: Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.